Are Some Degrees Better Than Others for Big Pharma Leaders?

Biopharmaceutical companies are under a great deal of financial pressure these days, and many are tinkering with long established business models. There can be no doubt that the industry is in flux as a result of pricing pressures from insurance companies, changing patent regulations and expirations, healthcare reform, and an increased focus on proving significant clinical benefits. Sadly, this is all taking place at a time when the largest biopharma companies have developed a black eye as a result of a seemingly endless series of ethical transgressions, including off-label drug promotions, hidden clinical trial outcomes, bribes and kickbacks for writing prescriptions, manufacturing breakdowns, and lawsuits tied to numerous medicines pulled off the market.